The FDA has approved Biomea's IND application to study BMF-219 in adults with type 1 diabetes, according to Biomea Fusion, Inc., a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to...
Bristol Myers Squibb, a US pharmaceutical corporation, announced a $4.8 billion deal to purchase cancer drugmaker Mirati Therapeutics. Bristol Myers Squibb will pay $58 per share in cash "for a total equity value of $4.8 billion," according to the...
The US Food and Drug Administration (FDA) has approved EntroGen's CRCdx RAS Mutation Detection Kit as a companion diagnostic for Vectibix (panitumumab), a colorectal cancer targeted therapy. This historic premarket approval (PMA) represents a...
India and Taiwan have formed a new partnership to develop and promote breakthrough health-tech solutions. The International Trade Administration, Government of Taiwan, and the Commerce Development Research Institute (CDRI), as the Taiwan...
Deuruxolitinib is an experimental medication for the treatment of moderate to severe alopecia areata, and Sun Pharmaceutical Industries Ltd. has reported that the United States Food and Drug Administration (USFDA) has approved its new drug...
Sai Life Sciences, the fastest-growing contract research, development, and manufacturing company in India, has chosen Dassault Systèmes' solutions to boost productivity, improve data quality, and promote collaboration in its research and...
Transcenta Holding Limited, a clinical stage biopharmaceutical company, announces that the FDA has approved the TranStar 301 global phase III pivotal trial of Osemitamab (TST001) in combination with Nivolumab and chemotherapy as first-line...
For many years, the discipline of drug formulation has been a pillar of the pharmaceutical business.
The US Food and Drug Administration (FDA) has released new draft recommendations to help sponsors develop therapies for stimulant use disorders. When it is completed, the guidance, Stimulant Use Disorders: Developing Drugs for Treatment, will be...
Sanofi and Teva Pharmaceuticals, a US division of Teva Pharmaceutical Industries Ltd., announce a partnership to co-develop and co-commercialize TEV'574, an inflammatory bowel disease treatment drug currently undergoing phase 2b clinical trials...
, CDSCO.jpg)
